
-
Molecular Templates OTC Markets EXMKT:MTEM Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases in the United States. The company develops therapies through its proprietary biologic drug platform technology (ETB). It is also developing MT- 8421, an ETB candidate that is in Phase I clinical trial for the treatment of dismantling TME through direct cell-kill of tumor and immune cell; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory multiple myeloma; and MT-6402 in that is in Phase I clinical trial for relapsed/refractory patients with PD-L1 expressing tumors. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas. On April 20, 2025, Molecular Templates, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Location: 9301 Amberglen Boulevard, Austin, TX, 78729, United States | Website: https://www.mtem.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
1.371M
Cash
9.657M
Avg Qtr Burn
-5.981M
Short % of Float
5.26%
Insider Ownership
3.96%
Institutional Own.
13.25%
Qtr Updated
06/30/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
MT-6402 Details Solid tumor/s, Cancer | Phase 1 Data readout | |
MT-8421 Details Cancer, Solid tumor/s | Phase 1 Data readout | |
MT-0169 Details Hematologic malignancies | Phase 1 Initiation | |
MT-0169 (TAK-169) (CD38) Details Multiple myeloma, Extramedullary myeloma | Failed Discontinued | |
MT-3724 (CD20) monotherapy Details DLBCL (Diffuse large B-cell lymphoma) | Failed Discontinued | |
MT-3724 (CD20) with Lenalidomide Details DLBCL (Diffuse large B-cell lymphoma) | Failed Discontinued | |
MT-5111 Details Breast cancer, Cancer | Failed Discontinued | |
MT-3724 with GEMOX (CD20) Details DLBCL (Diffuse large B-cell lymphoma) | Failed Discontinued |